Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
135
resultados
Última actualización
25/09/2025 [07:04:00]
Resumen de: WO2024105235A1
The disclosure relates to a pharmaceutical composition comprising human plasma-derived polyclonal, anti-SARS-CoV-2 hyperimmune globulins and to said pharmaceutical composition for use in the treatment of a SARS-CoV-2 Omicron variant infection. The disclosure also relates to a method for the preparation of a polyclonal, hyperimmune globulin composition anti-SARS-CoV-2.
Resumen de: WO2025189658A1
The present invention relates to a recombinant protein vaccine for preventing and treating SARS-CoV-2 variants JN.1, BA.2.86, and XBB lineages, a drug for combined use, and use. To solve the problem that Omicron JN.1, BA.2.86, and XBB lineage subvariants exhibit significant immune escape and blotting immunity after previous vaccination and viral infection, an XBB.1.5 recombinant protein vaccine is provided. The vaccine, when administered either intramuscularly or intranasally, induces strong humoral, cellular, and mucosal immune responses against JN.1, BA.2.86, and XBB lineage variants. Compared with homologous vaccination, after inactivated or mRNA vaccines are applied, the vaccine is used for heterologous vaccination to obtain a better immune response. Moreover, the vaccine induces effective protective immunity in vivo against Omicron EG.5.1 live virus attacks. Thus, the XBB.1.5 vaccine has clinical efficacy.
Resumen de: WO2025189415A1
The present invention relates to a recombinant protein vaccine for preventing and treating SARS-CoV-2 variant JN.1, BA.2.86, and XBB lineages, a combination drug, and a use. To address significant immune escape and immune imprinting phenomena observed with Omicron JN.1, BA.2.86 and XBB lineage subvariants following prior vaccination or virus infection, an XBB.1.5 recombinant protein vaccine is provided. This vaccine elicits potent humoral and cellular immune responses against currently circulating JN.1, BA.2.86, and XBB lineage variants. Compared with homologous vaccination, heterologous vaccination with this vaccine following administration of an inactivated or mRNA-based vaccine achieves superior immune responses. Moreover, the vaccine induces effective protective immunity against live Omicron EG.5.1 virus attack in vivo. Therefore, the monovalent XBB.1.5 vaccine has clinical use value.
Resumen de: US2025288542A1
Provided herein is a method for one or mor of preventing, treating, reducing the severity of acute respiratory distress syndrome (ARDS) in a subject at risk for contracting ARDS and infected with a coronavirus or SARS-CoV-2, comprising administering to the subject metformin, an analog or a derivative thereof, thereby preventing, treating, or reducing the severity of ARDS in the subject.
Resumen de: WO2025191011A1
The present invention refers to an agent for use in the prevention and/or treatment of lung pathological conditions associated with loss of alveolar epithelial type II to type I trans- differentiation capacity and/or with loss of lung regenerative capacity and/or for use in promoting lung regeneration in a subject with a lung pathological condition, said agent being selected from the group consisting of: an inhibitor of miR-210-3p and an inhibitor of miR-155- 5p or a combination thereof, wherein said lung pathological condition is selected from the group consisting of idiopathic pulmonary fibrosis, non-specific interstitial pneumonia, desquamative interstitial pneumonia, respiratory bronchiolitis-ILD, cryptogenic organizing pneumonia and acute interstitial pneumonia, chronic obstructive pulmonary disease, post-acute respiratory distress syndrome, and post-acute COVID-19 syndrome.
Resumen de: WO2025192852A1
The present invention relates to an antibody mRNA for treating SARS-coronavirus-2 delta infection and a composition including same, the composition exhibiting excellent therapeutic efficacy against SARS-coronavirus-2 delta infection.
Resumen de: WO2025192851A1
The present invention relates to an antibody mRNA for treating SARS-coronavirus-2 delta infection and a composition comprising same, which exhibits excellent therapeutic efficacy against SARS-coronavirus-2 delta infection.
Resumen de: US2025289826A1
Disclosed in the present invention are a PLpro protease inhibitor, and a preparation method and application thereof. The PLpro protease inhibitor can be combined with one or more pharmaceutically acceptable auxiliary materials or one or more other active ingredients to serve as a PLpro inhibitor to treat diseases caused by or diseases related to virus infection. The auxiliary material can be a carrier, a diluent, an adhesive, a lubricant, a wetting agent, etc. The protease inhibitor has high inhibitory activity, and can be used for broad-spectrum antivirals, especially for coronaviruses, for example, HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU, SARS-CoV, MERS-CoV, SARS-CoV-2, etc., in particular SARS-CoV, MERS-CoV, SARS-CoV-2.
Resumen de: US2025290165A1
The invention provides compositions and methods allowing for rapid detection of SARS-CoV-2 variants.
Resumen de: US2025289871A1
The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to the spike protein of SARS-CoV-2 and methods of making and using the same. The antibodies can be used, for example, in prophylaxis, post-exposure prophylaxis, or treatment of SARS-CoV-2 infection. The antibodies can also be used to detect SARS-CoV-2, e.g., an infection in subject.
Resumen de: US2025288547A1
Up-regulation of caspase has been found in COVID-19 patients, and also occurs in patients suffering from diabetes, hypertension, metabolic syndrome, and other conditions. Such up-regulation can be responsible for poor clinical outcomes in patients having such diseases or disorders, as such up-regulation leads to a process called pyroptosis: death and malfunction of immune system cells, particularly of certain types of lymphocytes. An inhibitor of caspase such as a caspase 1 inhibitor, or “pan-caspase” inhibitor (i.e., an inhibitor of multiple caspase types including caspase-1), can be used to treat COVID-19 patients or individuals at risk of infection, by limiting the malfunction of the immune system. A caspase-1 or pan-caspase inhibitor is advantageously administered before or very early in the course of infection by a positive-sense, single-stranded RNA virus such as SARS-COV, MERS-COV, or SARS-Cov-2.
Resumen de: AU2023375894A1
The disclosure provides, in various embodiments, polypeptides (e.g, antibodies and antigen binding fragments thereof) that specifically bind to receptor binding domains (RBDs) of betacoronavirus Spike glycoproteins, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike glycoproteins. The disclosure also provides, in various embodiments, fusion proteins comprising one or more of polypeptides, polynucleotides encoding polypeptides, vectors and host cells suitable for expressing polypeptides, and methods for treating viral infections (e.g., COVID-19).
Resumen de: WO2025187767A1
One problem to be addressed by the present invention is to provide a drug which is capable of suppressing the proliferation of SARS-CoV-2 with high efficiency. Another problem to be addressed by the present invention is to provide a drug which exhibits an inhibitory effect on a wide range of coronaviruses and thereby can immediately respond to the pandemic of unknown SARS-CoV-2 mutants and new types of coronaviruses which could happen in the future. Provided is an oligonucleotide or a pharmaceutically acceptable salt thereof, wherein: the oligonucleotide comprises an oligonucleotide that is composed of 17-30 nucleotides and comprises a nucleotide sequence and is complementary to a region lying between a nucleotide located at position-13520 to a nucleotide located at position-13550 in SARS-CoV-2 RNA genome comprising the nucleotide sequence represented by SEQ ID NO: 1; and the oligonucleotide is a mixmer and is capable of inhibiting the viral proliferation of coronaviruses, wherein the 5'-end and/or the 3'-end of the oligonucleotide may be chemically modified. Also provided is a drug comprising the oligonucleotide or a pharmaceutically acceptable salt thereof.
Resumen de: WO2025189138A1
An affinity membrane separator is provided that includes a separation substrate with a plurality of peptide ligands positioned thereon. The peptide ligands preferentially bind to one of a nucleic acid product and a waste nucleic acid product, e.g., produced by a mRNA synthesis bioreactor. The peptide ligands include fewer than 20 residues and at least one defined secondary structure, and have a global charge greater than about 1 and at least one lysine, arginine, or glutamine residue in order to preferentially bind ds-RNA relative to ss-RNA, or a global charge less than about 0 and at least one serine or asparagine residue in order to preferentially bind ss-RNA relative to ds-RNA. Peptide ligands can advantageously bind to ds-RNA byproducts from the production of ss-RNA vaccines, e.g., against SARS-CoV-2, while allowing the ss-RNA vaccines themselves to pass through the separator, providing an efficient system for production of purified ss-RNA vaccine products.
Resumen de: WO2025189041A1
Described herein are methods and compositions for treating fibrosis, particularly pulmonary fibrosis. The pulmonary fibrosis may be idiopathic or arise following an infection of the lung. The lung infection can be by SARS-CoV-2. Lung function stabilizes or is improved as a result of treatment.
Resumen de: WO2025186660A1
The present invention relates to second-generation vaccine against COVID-19 to abrogate or diminish the binding of the SARS-CoV-2 spike (S) protein, or part of it, to the human angiotensin-converting enzyme 2 (hACE2). Such vaccines present several advantages as to avoid pathways of immune dysregulation activated following S protein/hACE2 interaction while maintaining the ability to elicit a strong and robust antibody neutralization response to SARS-CoV-2. The invention relates also to the use of the S protein for therapeutic uses and for vaccines in the prevention or treatment of SARS-CoV-2 infection or conditions or disorders resulting from such infection.
Resumen de: US2025282832A1
A chimeric nucleotide sequence that corresponds to an encoded fusion protein comprising a polyepitope resulting from selecting and juxtaposing multiple epitopes from a coronavirus protein to induce an immune response in mammals. In one embodiment, said fusion protein comprises: a) a first peptide consisting of epitopes found in the amino acid sequence of replicase polyprotein 1ab (PR1ab); b) a first spacer; c) a modified form of herpes simplex virus type 1 (HSV-1) glycoprotein D (gD). In one embodiment, the replicase polyprotein is defined by SEQ ID NO: 96 flanked by a gD fragment comprising the amino acid sequence defined by SEQ ID NO: 98 in the N-terminal portion and another gD fragment comprising the amino acid sequence defined by SEQ ID NO: 100 in the C-terminal region. Use of the fusion protein has surprising results in inducing cellular and humoral immune responses against coronavirus, SARS-COV-2, and related viruses.
Resumen de: AU2024230449A1
The present specification provides methods and compositions for treating fibrosis, particularly pulmonary fibrosis. The pulmonary fibrosis may be idiopathic or arise following an infection of the lung. The lung infection can be by SARS-CoV-2. Lung function stabilizes or is improved as a result of treatment.
Resumen de: US2025283880A1
The present invention provides a sensitizer for immunochromatographic assay capable of detecting novel coronavirus (SARS-CoV-2) IgM antibodies and/or IgG antibodies with high sensitivity, and an assay using the sensitizer. Specifically, the present invention provides a sensitizer for immunochromatographic assay for novel coronavirus (SARS-CoV-2) IgM antibodies and/or IgG antibodies as assay target substances, that contains a polymer represented by the following formula 4:wherein m, n, and p are each a constitutional unit number, an m:n:p is 100 to 30:0 to 70:0 to 50.
Resumen de: US2025283882A1
The present disclosure relates to the use of DNA-peptide hybrid molecules to detect target molecules in a sample. In some embodiments, the DNA-peptide hybrid molecules comprise target-specific binding peptides which selectively bind to a target molecule. Kits comprising DNA-peptide hybrid molecules are also provided.
Resumen de: US2025283881A1
The present disclosure provides systems and processes to screen for SARS-CoV-2. This disclosure teaches specific (and different) workable ranges for starting materials in a screening process for different SARS-CoV-2 variants (e.g., the Washington isolate, Alpha variant, Gamma P.1 variant, Beta variant, Iota variant, Delta variant, Omicron BA.1 variants, etc.). As shown herein, each variant has a different combination of starting materials and incubation periods, which further demonstrates the unpredictability of success that is associated with the disclosed systems and the disclosed processes. To be clear, the general ELISA process is well known by those having skill in the art. However, what is neither well known nor intuitive are the specific parameters associated with different process steps within ELISA. Those specific parameters are the subject of this disclosure.
Resumen de: LU509898B1
The present invention belongs to the technical field of traditional Chinese medicine, and discloses a traditional Chinese medicine prescription for preventing and treating COVID-19, which is composed of the following weight components: 9 to 15 grams of wild chrysanthemum, 6 to 15 grams of Artemisia annua, 10 to 20 grams of mint, and 3 to 15 grams of Elsholtzia. The formula of the present invention is scientific and reasonable, and the drug effect reaches the affected part directly, which can reduce fever, relieve cough, and resolve phlegm, quickly relieve sore throat, dry and hot throat, and peeling lips, and can effectively prevent and inhibit the occurrence and recurrence rate of COVID-19, and at the same time has the advantages of fast effect and fast recovery of physical strength.
Resumen de: US2025281606A1
The present invention relates to a pharmaceutical composition comprising therapeutically effective amount of Cannabidiol for administration with a Covid-19 vaccine to a mammal/human to sustain and/or enhance effect of vaccine. Further the invention relates to methods to sustain and/or enhance effect of a Covid-19 vaccine in a mammal/human by administering to such a mammal/human a pharmaceutical composition comprising a therapeutically effective amount of Cannabidiol with a Covid-19 vaccine.Administration of Cannabidiol with vaccine can be of following types: i) before administering Covid-19 vaccine; or ii) along with Covid-19 vaccine; or iii) after administering Covid-19 vaccine; or iv) any combination of i, ii and iii including before, along with and after administering Covid-19 vaccine.
Resumen de: US2025281601A1
The invention relates to vaccination of human subjects, in particular elderly, against bacterial infections, wherein the bacterial infection is not pneumococcal, and COVID-19 infections.
Nº publicación: US2025281393A1 11/09/2025
Solicitante:
CS MEDICA AS [DK]
CS MEDICA A/S
Resumen de: US2025281393A1
The present invention relates to non-psychoactive cannabinoid-comprising compositions, said compositions comprising cannabidiol (CBD) formulated for application in a body cavity, such as a gel for intranasal application. Said composition comprises CBD; glycol(s); emulsifier(s), including non-ionic emulsifier(s); NaCl; panthenol; hyaluronic acid/salt; phytic acid and water, and optionally one or more of gelling agent, allantoin, and/or pH regulator. Such compositions can be used in the context of protection against pathogens and/or in reduction of ingress of infectious and/or irritating agents such as dust, pollen, microorganism(s), bacteria, fungi, and/or virus, such as COVID-19.
BOPI
Sede Electrónica
